Design and Synthesis of Basic Selective Estrogen Receptor Degraders for Endocrine Therapy Resistant Breast Cancer

The clinical steroidal selective estrogen receptor (ER) degrader (SERD), fUlvestrant, is effective in metastatic breast cancer, but limited by poor pharmacokinetics, prompting the development of orally bioavailable, nonsteroidal SERDs, currently in clinical trials. These trials address local breast...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Med Chem
Hlavní autoři: Lu, Yunlong, Gutgesell, Lauren M., Xiong, Rui, Zhao, Jiong, Li, Yangfeng, Rosales, Carlo I., Hollas, Michael, Shen, Zhengnan, Gordon-Blake, Jesse, Dye, Katherine, Wang, Yueting, Lee, Sue, Chen, Hu, He, Donghong, Dubrovyskyii, Oleksii, Zhao, Huiping, Huang, Fei, Lasek, Amy W., Tonetti, Debra A., Thatcher, Gregory R. J.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2019
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7261373/
https://ncbi.nlm.nih.gov/pubmed/31746603
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acs.jmedchem.9b01580
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky